These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 20409934)

  • 1. Does it matter how blood pressure is lowered in patients with metabolic risk factors?
    Sharma AM
    J Am Soc Hypertens; 2008; 2(4 Suppl):S23-9. PubMed ID: 20409934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin-angiotensin-system blockade in the prevention of diabetes.
    Ostergren J
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S13-21. PubMed ID: 17320999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management issues in the metabolic syndrome.
    Deedwania PC; Gupta R
    J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention.
    Towfighi A; Ovbiagele B
    Cerebrovasc Dis; 2008; 26(2):106-12. PubMed ID: 18560212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation multifunctional angiotensin receptor blockers.
    Kurtz TW; Klein U
    Hypertens Res; 2009 Oct; 32(10):826-34. PubMed ID: 19713966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system.
    Cooper ME; Tikellis C; Thomas MC
    J Hypertens Suppl; 2006 Mar; 24(1):S57-63. PubMed ID: 16601575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
    Abuissa H; Jones PG; Marso SP; O'Keefe JH
    J Am Coll Cardiol; 2005 Sep; 46(5):821-6. PubMed ID: 16139131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic considerations in hypertension.
    Tuck ML
    Am J Hypertens; 1990 Dec; 3(12 Pt 2):355S-365S. PubMed ID: 2078323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-diabetic effect of blockade of the renin-angiotensin system.
    Ando K; Fujita T
    Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
    Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
    Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction.
    Mancia G
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S17-25. PubMed ID: 15868115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence.
    Abdellatif AA
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):251-63. PubMed ID: 22292880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.